{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T12:40:50Z","timestamp":1765888850400,"version":"3.37.3"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,4,11]],"date-time":"2022-04-11T00:00:00Z","timestamp":1649635200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,4,11]],"date-time":"2022-04-11T00:00:00Z","timestamp":1649635200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"FCT - Foundation for Science and Techonology,","award":["UIDB00276\/2020 (funded by FCT)"],"award-info":[{"award-number":["UIDB00276\/2020 (funded by FCT)"]}]},{"name":"CECAV - Veterinary and Animal Research Center","award":["LA\/P\/0059\/2020"],"award-info":[{"award-number":["LA\/P\/0059\/2020"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Parasites Vectors"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Proteinuria is a common finding in dogs with leishmaniosis. Although antileishmanial therapeutic protocols are widely implemented, little information is available on which treatments are most adequate for identifying proteinuria in patients with canine leishmaniosis (CanL), especially regarding the use of immunosuppressants. The aim of this study was to explore the current paradigm regarding the antiproteinuric approach adopted by veterinary practitioners in Portugal to treat dogs with CanL.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A questionnaire-based study was developed using Google Forms\u00ae. The questionnaire presented a number of different hypothetical scenarios of CanL, and the topics surveyed included the general features of the respondents and the protocols preferred by these respondents to manage proteinuria in the presented scenarios, including choice of therapeutic drugs, appropriate diet and use of immunosuppressants, in dogs with immune-mediated glomerulonephritis. The questionnaire was internally prevalidated and diffused online over a 2-month period through Portuguese veterinary social networking groups, and data were collected for descriptive analysis.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>A total of 86 veterinary practitioners responded to the survey. When exposed to theoretical scenarios of proteinuria in dogs with CanL at stages IIb, III and IV (LeishVet guidelines), 16.3%, 62.8% and 93.8% of the respondents, respectively, answered that they would treat it. The dog was started on a renal diet as therapy by 28.6%, 83.3% and 97.4% of respondents, respectively. Angiotensin-converting enzyme inhibitors (ACEI) were prescribed by 100%, 85.2% and 78.9% of respondents as first-choice drugs for CanL at stages IIb, III and IV, respectively, with ACEI used in monotherapy by 64.3%, 40.7% and 46.1%. In comparison, protocols using ACEI in combination with other compounds were chosen by 7.1%, 33.3% and 39.5% of respondents, and combination therapy which did not include ACEI was the choice of 0.0%, 12.9% and 14.5%. Regarding immunosuppressants, 44.2% of the respondents answered they would prescribe them, with 97.4% electing for prednisolone and 5.3% choosing mycophenolate mofetil.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Among the veterinary practitioners who responded, proteinuria treatment was considered since stage IIb CanL, although implementation of a therapeutic approach was more evident in advanced CanL stages. ACEI were the first-choice drugs, particularly for the treatment of stage IIb CanL; in advanced stages, a combination of antiproteinuric drugs was more often used. Immunosuppressant use was controversial, although when applied, prednisolone was the preferred choice. These findings reinforce the small body of evidence that supports the use of such drugs and the need to further explore their role in CanL.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Graphical Abstract<\/jats:title>\n                \n              <\/jats:sec>","DOI":"10.1186\/s13071-022-05222-w","type":"journal-article","created":{"date-parts":[[2022,4,11]],"date-time":"2022-04-11T11:06:33Z","timestamp":1649675193000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Dogs with leishmaniosis: how are we managing proteinuria in daily practice? A Portuguese questionnaire-based study"],"prefix":"10.1186","volume":"15","author":[{"given":"Marta","family":"Monteiro","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Prata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lu\u00eds","family":"Cardoso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabel","family":"Pereira da Fonseca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2463-4062","authenticated-orcid":false,"given":"Rodolfo Oliveira","family":"Leal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,4,11]]},"reference":[{"key":"5222_CR1","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/j.pt.2012.08.007","volume":"28","author":"F Dantas-Torres","year":"2012","unstructured":"Dantas-Torres F, Solano-Gallego L, Baneth G, Ribeiro VM, de Paiva-Cavalcanti M, Otranto D. Canine leishmaniosis in the Old and New Worlds: unveiled similarities and differences. Trends Parasitol. 2012;28:531\u20138.","journal-title":"Trends Parasitol"},{"key":"5222_CR2","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.vetpar.2015.05.003","volume":"213","author":"C Maia","year":"2015","unstructured":"Maia C, Cardoso L. Spread of Leishmania infantum in Europe with dog travelling. Vet Parasitol. 2015;213:2\u201311.","journal-title":"Vet Parasitol"},{"key":"5222_CR3","unstructured":"European Scientific Counsel Companion Animal Parasites (ESCCAP). Control of vector-borne diseases in dogs and cats. 2019. https:\/\/www.esccap.org\/guidelines\/gl5\/. Accessed 30 Dec 2020."},{"key":"5222_CR4","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1177\/0300985814521248","volume":"51","author":"AF Koutinas","year":"2014","unstructured":"Koutinas AF, Koutinas CK. Pathologic mechanisms underlying the clinical findings in canine leishmaniasis due to Leishmania infantum\/chagasi. Vet Pathol. 2014;51:527\u201338.","journal-title":"Vet Pathol"},{"key":"5222_CR5","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1111\/j.1939-1676.2006.tb01809.x","volume":"20","author":"O Cortadellas","year":"2006","unstructured":"Cortadellas O, Fern\u00e1ndez-del Palacio MJ, Bay\u00f3n A, Albert A, Talavera J. Systemic hypertension in dogs with leishmaniasis: prevalence and clinical consequences. J Vet Intern Med. 2006;20:941\u20137.","journal-title":"J Vet Intern Med"},{"key":"5222_CR6","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1354\/vp.40-6-677","volume":"40","author":"FAL Costa","year":"2003","unstructured":"Costa FAL, Goto H, Saldanha LCB, Silva SMMS, Sinhorini IL, Silva TC, et al. Histopathologic patterns of nephropathy in naturally acquired canine visceral leishmaniasis. Vet Pathol. 2003;40:677\u201384.","journal-title":"Vet Pathol"},{"key":"5222_CR7","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1111\/vcp.12413","volume":"45","author":"S Paltrinieri","year":"2016","unstructured":"Paltrinieri S, Gradoni L, Roura X, Zatelli A, Zini E. Laboratory tests for diagnosing and monitoring canine leishmaniasis. Vet Clin Pathol. 2016;45:552\u201378.","journal-title":"Vet Clin Pathol"},{"key":"5222_CR8","unstructured":"LeishVet. LeishVet guidelines for the practical management of canine and feline leishmaniosis: a brief for the practicing veterinarian. 2018. http:\/\/www.leishvet.org\/wp-content\/uploads\/2018\/09\/EN-Guidelines.pdf. Accessed 2 Mar 2020."},{"key":"5222_CR9","doi-asserted-by":"crossref","unstructured":"Roura X, Cortadellas O, Day MJ, Benali SL, Canine Leishmaniosis Working Group, Zatelli A. Canine leishmaniosis and kidney disease: Q&A for an overall management in clinical practice. J Small Anim Pract. 2021;62:E1\u2013E19.","DOI":"10.1111\/jsap.13237"},{"key":"5222_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1756-3305-4-86","volume":"4","author":"L Solano-Gallego","year":"2011","unstructured":"Solano-Gallego L, Mir\u00f3 G, Koutinas A, Cardoso L, Pennisi MG, Ferrer L, et al. LeishVet guidelines for the practical management of canine leishmaniosis. Parasit Vectors. 2011;4:1\u201316.","journal-title":"Parasit Vectors"},{"key":"5222_CR11","doi-asserted-by":"publisher","first-page":"362","DOI":"10.3389\/fvets.2019.00362","volume":"6","author":"MF Santos","year":"2019","unstructured":"Santos MF, Alexandre-Pires G, Pereira MA, Marques CS, Gomes J, Correia J, et al. Meglumine antimoniate and miltefosine combined with allopurinol sustain pro-inflammatory immune environments during canine leishmaniosis treatment. Front Vet Sci. 2019;6:362.","journal-title":"Front Vet Sci"},{"key":"5222_CR12","doi-asserted-by":"publisher","first-page":"375","DOI":"10.3389\/fvets.2020.00375","volume":"7","author":"MF Santos","year":"2020","unstructured":"Santos MF, Alexandre-Pires G, Pereira MA, Gomes L, Rodrigues AV, Basso A, et al. Immunophenotyping of peripheral blood, lymph node, and bone marrow t lymphocytes during canine leishmaniosis and the impact of antileishmanial chemotherapy. Front Vet Sci. 2020;7:375.","journal-title":"Front Vet Sci"},{"key":"5222_CR13","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.2460\/javma.236.11.1192","volume":"236","author":"G Oliva","year":"2010","unstructured":"Oliva G, Roura X, Crotti A, Maroli M, Castagnaro M, Gradoni L, Lubas G, Paltrinieri S, Zatelli A, Zini E. Guidelines for treatment of leishmaniasis in dogs. J Am Vet Med Assoc. 2010;236:1192\u20138.","journal-title":"J Am Vet Med Assoc"},{"key":"5222_CR14","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1186\/s13071-021-04799-y","volume":"14","author":"M Monteiro","year":"2021","unstructured":"Monteiro M, Prata S, Cardoso L, Pereira da Fonseca I, Leal RO. Diagnosis and clinical management of canine leishmaniosis by general veterinary practitioners: a questionnaire-based survey in Portugal. Parasit Vectors. 2021;14:306.","journal-title":"Parasit Vectors"},{"key":"5222_CR15","unstructured":"International Renal Interest Society (IRIS). IRIS Staging of CKD. 2019. http:\/\/www.iris-kidney.com\/guidelines\/staging.html. Assessed 15 Apr 2020."},{"key":"5222_CR16","unstructured":"International Renal Interest Society (IRIS). Treatment Recommendations for CKD in Dogs. 2019. http:\/\/www.iris-kidney.com\/guidelines\/recommendations.html. Assessed 29 Apr 2020."},{"key":"5222_CR17","doi-asserted-by":"publisher","first-page":"S27","DOI":"10.1111\/jvim.12230","volume":"27","author":"S Brown","year":"2013","unstructured":"Brown S, Elliott J, Francey T, Polzin D, Vaden S. Consensus recommendations for standard therapy of glomerular disease in dogs. J Vet Intern Med. 2013;27:S27\u201343.","journal-title":"J Vet Intern Med"},{"key":"5222_CR18","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1111\/jvim.12232","volume":"27","author":"G Segev","year":"2013","unstructured":"Segev G, Cowgill LD, Heiene R, Labato MA, Polzin DJ. Consensus recommendations for immunosuppressive treatment of dogs with glomerular disease based on established pathology. J Vet Intern Med. 2013;27:60\u20136.","journal-title":"J Vet Intern Med"},{"key":"5222_CR19","doi-asserted-by":"publisher","first-page":"231","DOI":"10.5326\/JAAHA-MS-5840","volume":"49","author":"M Pierantozzi","year":"2013","unstructured":"Pierantozzi M, Roura X, Paltrinieri S, Poggi M, Zatelli A. Variation of proteinuria in dogs with leishmaniasis treated with meglumine antimoniate and allopurinol: a retrospective study. J Am Anim Hosp Assoc. 2013;49:231\u20136.","journal-title":"J Am Anim Hosp Assoc"},{"key":"5222_CR20","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/412808","volume":"2014","author":"D Proverbio","year":"2014","unstructured":"Proverbio D, Spada E, Bagnagatti De Giorgi G, Perego R, Valena E. Relationship between Leishmania IFAT titer and clinicopathological manifestations (clinical score) in dogs. Biomed Res Int. 2014;2014: 412808.","journal-title":"Biomed Res Int"},{"key":"5222_CR21","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1111\/j.1939-1676.2005.tb02713.x","volume":"19","author":"GE Lees","year":"2005","unstructured":"Lees GE, Brown SA, Elliott J, Grauer GF, Vaden SL. Assessment and management of proteinuria in dogs and cats: 2004 ACVIM Forum Consensus Statement (Small Animal). J Vet Intern Med. 2005;19:377\u201385.","journal-title":"J Vet Intern Med"},{"key":"5222_CR22","doi-asserted-by":"publisher","first-page":"S60","DOI":"10.1111\/jvim.12232","volume":"27","author":"RE Goldstein","year":"2013","unstructured":"Goldstein RE, Brovida C, Fern\u00e1ndez-Del Palacio MJ, Littman MP, Polzin DJ, Zatelli A, et al. Consensus recommendations for treatment for dogs with serology positive glomerular disease. J Vet Intern Med. 2013;27:S60\u20136.","journal-title":"J Vet Intern Med"},{"key":"5222_CR23","doi-asserted-by":"publisher","first-page":"S19","DOI":"10.1111\/jvim.12223","volume":"27","author":"MP Littman","year":"2013","unstructured":"Littman MP, Daminet S, Grauer GF, Lees GE, van Dongen AM. Consensus recommendations for the diagnostic investigation of dogs with suspected glomerular disease. J Vet Intern Med. 2013;27:S19\u201326.","journal-title":"J Vet Intern Med"},{"key":"5222_CR24","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1111\/jvim.16146","volume":"35","author":"J Lecavalier","year":"2021","unstructured":"Lecavalier J, Fifle L, Javard R. Treatment of proteinuria in dogs with telmisartan: a retrospective study. J Vet Intern Med. 2021;35:1810\u20138.","journal-title":"J Vet Intern Med"},{"key":"5222_CR25","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1111\/jvim.16102","volume":"35","author":"BL Fowler","year":"2021","unstructured":"Fowler BL, Stefanovski D, Hess RS, McGonigle K. Effect of telmisartan, angiotensin-converting enzyme inhibition, or both, on proteinuria and blood pressure in dogs. J Vet Intern Med. 2021;35:1231\u20137.","journal-title":"J Vet Intern Med"},{"key":"5222_CR26","doi-asserted-by":"publisher","first-page":"2478","DOI":"10.1111\/jvim.15958","volume":"34","author":"BN Louren\u00e7o","year":"2020","unstructured":"Louren\u00e7o BN, Coleman AE, Brown SA, Schmiedt CW, Parkanzky MC, Creevy KE. Efficacy of telmisartan for the treatment of persistent renal proteinuria in dogs: a double-masked, randomized clinical trial. J Vet Intern Med. 2020;34:2478\u201396.","journal-title":"J Vet Intern Med"},{"key":"5222_CR27","unstructured":"Ordem dos M\u00e9dicos Veterin\u00e1rios (OMV). Estat\u00edsticas. 2020. https:\/\/www.omv.pt\/omv\/estatisticas. Assessed 1 Aug 2020."},{"key":"5222_CR28","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/j.tvjl.2014.03.033","volume":"200","author":"MJ Mattin","year":"2014","unstructured":"Mattin MJ, Solano-Gallego L, Dhollander S, Afonso A, Brodbelt DC. The frequency and distribution of canine leishmaniosis diagnosed by veterinary practitioners in Europe. Vet J. 2014;200:410\u20139.","journal-title":"Vet J"},{"key":"5222_CR29","first-page":"21","volume":"109","author":"AM Oliveira","year":"2010","unstructured":"Oliveira AM, Diaz S, Santos C, Bourdeau P, Pereira da Fonseca I. Geographical distribution, clinical presentation, treatment and prevention of canine leishmaniosis in Portugal: a 2007 field survey. Rev Port Cienc Vet. 2010;109:21\u20139.","journal-title":"Rev Port Cienc Vet"}],"container-title":["Parasites &amp; Vectors"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13071-022-05222-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13071-022-05222-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13071-022-05222-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,11]],"date-time":"2022-04-11T11:10:10Z","timestamp":1649675410000},"score":1,"resource":{"primary":{"URL":"https:\/\/parasitesandvectors.biomedcentral.com\/articles\/10.1186\/s13071-022-05222-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,11]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["5222"],"URL":"https:\/\/doi.org\/10.1186\/s13071-022-05222-w","relation":{},"ISSN":["1756-3305"],"issn-type":[{"type":"electronic","value":"1756-3305"}],"subject":[],"published":{"date-parts":[[2022,4,11]]},"assertion":[{"value":"10 December 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"125"}}